FDA extends review for Novo Nordisk's denecimig for hemophilia A

source: news (news:seeking-alpha)published 2026-10-02 21:27ingested 2026-10-03 02:55

retained text

Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in

FDA extends review for Novo Nordisk's denecimig for hemophilia A

Oct 02, 2026, 5:27 PM ETNovo Nordisk A/S (NVO) StockBy : Jonathan Block, SA News Editor

The USA FDA has extended its review of Novo Nordisk's (NVO) BLA seeking approval of denecimig for hemophilia A.

The Danish pharma said that ongoing facility remediation activities at a manufacturing site for the drug are the reason for the

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

document fetched 2026-10-03 02:55 · canonical https://seekingalpha.com/news/4650001-fda-extends-review-novo-nordisk-denecimig-hemophilia-a?feed_item_type=news